Transitioning from Phase III Success to Commercial Activities: Ensuring Pre-Launch Readiness in the Alzheimer’s Treatment Landscape
Time: 2:00 pm
day: Conference Day Two - Track Three
Details:
- Showcasing the positive clinical results of blarcamesine as a novel oral therapy for AD
- Outlining key components of market research to support pre-launch readiness activities
- Highlighting key commercial bottlenecks to consider and anticipate in preparations
